Erratum: Darolutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer: A Patient Perspective of the ARAMIS Trial (Future Oncology (2016) 17:14 (1699-1707) DOI: 10.2217/fon-2020-1291)

Following publication of the Plain Language Summary of Publication by K Fizazi, Ian Blue & Joel T Nowak, titled 'Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial', which appeared in the May 2021 issue of Future Oncology (Future Oncol. 17[14], 1699-1707 [2016]; DOI: 10.2217/fon-2020-1291), it has been brought to our attention that a data point in the table titled 'What were the adverse events that were most likely to affect participants' daily lives?' on page 1704 was incorrectly printed as 26. It has now been corrected to 46. The authors and editors of Future Oncology would like to sincerely apologise for any confusion or inconvenience this may have caused our readers.